STERIS plc (STE) has a MoatMap StockRank of 76/100 based on Quality (65/100), Value (41/100), and Momentum (52/100) factor scores. The current signal is BUY. STERIS is a high-moat global leader in sterilization services and infection prevention. It operates as an essential gatekeeper for biopharma CDMOs and medical device manufacturers. With extremely high switching costs, regulatory mandates, and an asset-light recurring service revenue model, STERIS possesses immense pricing power and fits the Terry Smith quality compounder profile perfectly.
STERIS plc is a global provider of infection prevention and other procedural products and services for healthcare, pharmaceutical, and research customers. Its competitive moat is built on its comprehensive portfolio of sterilization equipment, consumables, and services, strong regulatory compliance expertise, and established relationships within the healthcare sector, making it a market leader in infection control.
| Price | $212.24 |
| Market Cap | $21.1B |
| P/E (TTM) | 26.73 |
| P/E (Forward) | 17.54 |
| Price/Book | 2.89 |
| Return on Equity | 11.4% |
| Debt/Equity | 29.00 |
| Gross Margin | 44.2% |
| Operating Margin | 20.0% |
| Revenue Growth | 7.3% |
| Dividend Yield | 1.2% |
| Free Cash Flow | $837M |
STERIS plc operates in the Medical Devices industry, part of the Healthcare sector (United States).